Stopping trials prematurely: sorting the right decisions from the wrong

Anna Wagstaff

Allegations that commercial pressures may be leading to cancer drug trials being halted prematurely hit the news on both sides of the Atlantic last April. Industry leaders are pleading ‘not guilty’. But how can we judge when calling an early halt to a trial is the right thing to do?

Download full article

Be the first to comment

Leave a Reply

Your email address will not be published.


*


UA-77507851-1